Target intelligence / Profile preview

C-terminal domain nuclear envelope phosphatase 1 (CTDNEP1)

Target
CTDNEP1
Molecular classification
Enzyme (protein serine/threonine phosphatase), Member of the DXDX(T/V) phosphatase family, Subfamily: C-terminal domain phosphatases (CTDPs), part of the haloacid dehalogenase (HAD) superfamily
01

Overview

CTD nuclear envelope phosphatase 1 (CTDNEP1) is a magnesium-dependent, noncanonical protein serine/threonine phosphatase within the DXDX(T/V) phosphatase family. It forms a membrane protein complex with NEP1R1, its regulatory subunit, to dephosphorylate lipin family proteins and thereby regulate lipid biosynthesis and ER membrane expansion. CTDNEP1 is essential for maintaining proper ER and nuclear envelope morphology; its loss or inactivation leads to excessive ER expansion. Mutations in CTDNEP1 are linked to aggressive childhood medulloblastoma and may play roles in neural development by modulating BMP signaling. The molecular structure of the CTDNEP1–NEP1R1 complex has recently been elucidated, revealing mechanisms of substrate specificity, allosteric regulation, and the basis for cancer-associated mutations[1][2][3][4].

Other names
CTDNEP1DULLARDHSA011916NET56C-terminal domain nuclear envelope phosphatase 1Serine/threonine-protein phosphatase dullardDullard homolog
02

Mechanism of action

Drugs targeting this molecule would likely act by modulating its phosphatase activity or the CTDNEP1–NEP1R1 complex's ability to dephosphorylate lipin, thereby affecting ER biogenesis and lipid synthesis[1][2][3]. However, no clinically available drugs with this exact mechanism are listed in the present literature.

03

Biological functions

Regulation of ER membrane biogenesisLipid and membrane biosynthesis (via dephosphorylation of lipin)Neural development (inhibition of bone morphogenetic proteins, BMPs)Maintenance of nuclear envelope morphology
04

Disease associations

Cancer (particularly medulloblastoma; inactivating mutations are associated with this childhood brain tumor)Other potential roles in neural development and associated congenital disorders
05

Safety considerations

Therapeutic modulation of CTDNEP1 could impact lipid metabolism and ER function, with possible risks for neural development or other essential cellular processesOff-target inhibition might disrupt neural tube development or ER homeostasis
06

Interacting drugs

No currently approved drugs directly target CTDNEP1 as its primary mechanism of action, according to available sources.
07

Biomarkers

CTDNEP1 mutation status (potential biomarker for medulloblastoma prognosis)Lipin phosphorylation state may indirectly reflect CTDNEP1 activity

Beyond the preview

Go deeper on C-terminal domain nuclear envelope phosphatase 1 (CTDNEP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on C-terminal domain nuclear envelope phosphatase 1 (CTDNEP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call